



Corrigendum: Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting **Periostin-Mediated Renal Fibrosis**

Xiaoli Du^{1,2,3}, Qianqian Tao^{1,3}, Hongxia Du^{1,3}, Zhenbang Zhao², Yu Dong^{1,2}, Shuang He^{1,3}, Rui Shao 1,3, Yule Wang 1,3, Wenrun Han 1,3, Xintong Wang 1,3 and Yan Zhu 1,3*

OPEN ACCESS

Edited and reviewed by:

Shuai Ji Xuzhou Medical University, China

*Correspondence:

yanzhu.harvard@icloud.com

Specialty section:

This article was submitted to Ethnopharmacology. a section of the journal Frontiers in Pharmacology

Received: 13 November 2021 Accepted: 24 November 2021 Published: 31 January 2022

Citation:

Du X, Tao Q, Du H, Zhao Z, Dong Y, He S, Shao R, Wang Y, Han W, Wang X and Zhu Y (2022) Corrigendum: Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-Mediated Renal Fibrosis Front. Pharmacol. 12:814501. doi: 10.3389/fphar.2021.814501

¹Institute of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China, ²Department of Pharmacy, Inner Mongolia Medical College, Hohhot, China, ³Tianjin International Joint Academy of Biomedicine, Tianjin, China

Keywords: hypertension-induced kidney damage, periostin, TGFî²/SMAD signaling pathway, inflammatory response, human kidney HEK293 cells

A corrigendum on

Tengdan Capsule Prevents Hypertensive Kidney Damage in SHR by Inhibiting Periostin-**Mediated Renal Fibrosis**

by Du, X., Tao, Q., Du, H., Zhao, Z., Dong, Y., He, S., Shao, R., Wang, Y., Han, W., Wang, X., and Zhu, Y. Front. Pharmacol. 12:638298. doi: 10.3389/fphar.2021.638298

In the original article, there was a mistake in Figure 2 as published. The Figure 1 was accidentally duplicated in the proof stage. The correct Figure 2 appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Du, Tao, Du, Zhao, Dong, He, Shao, Wang, Han, Wang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.




FIGURE 2 Effects of TDC on noninvasive blood pressure in SHR (**A–C**) Representative data plots of SBP, DBP, and MBP measurements, respectively, over 4 weeks using the noninvasive tail-cuff method in conscious rats (**D**) Bar graph comparison of the MBP in the four rat groups at day 28. Data are expressed as mean \pm SD, n = 5-6. ****p < 0.0001 vs. WKY rats; ##p < 0.01, ###p < 0.001 vs. SHR.>